Want to take quizzes and track your credits?
What are the outcomes of liver transplants with grafts donated after euthanasia?
In this cohort study of 47 liver transplants with grafts donated after euthanasia in the Netherlands and Belgium, recipient and graft survival rates were comparable with the survival rates in a comparative cohort of 542 recipients of liver grafts from donors with a circulatory arrest after the withdrawal of life-supporting treatment. The use of liver grafts donated after euthanasia can expand the pool of grafts donated after circulatory death by approximately 7%.
Findings from this study suggest that the use of liver grafts donated after euthanasia is justifiable and can expand the existing liver donor pool.
The option of donating organs after euthanasia is not well known. Assessment of the results of organ transplants with grafts donated after euthanasia is essential to justify the use of this type of organ donation.
To assess the outcomes of liver transplants (LTs) with grafts donated after euthanasia (donation after circulatory death type V [DCD-V]), and to compare them with the results of the more commonly performed LTs with grafts from donors with a circulatory arrest after the withdrawal of life-supporting treatment (type III [DCD-III]).
Design, Setting, and Participants
This retrospective multicenter cohort study analyzed medical records and LT data for most transplant centers in the Netherlands and Belgium. All LTs with DCD-V grafts performed from the start of the donation after euthanasia program (September 2012 for the Netherlands, and January 2005 for Belgium) through July 1, 2018, were included in the analysis. A comparative cohort of patients who received DCD-III grafts was also analyzed. All patients in both cohorts were followed up for at least 1 year. Data analysis was performed from September 2019 to December 2019.
Liver transplant with either a DCD-V graft or DCD-III graft.
Main Outcomes and Measures
Primary outcomes were recipient and graft survival rates at years 1, 3, and 5 after the LT. Secondary outcomes included postoperative complications (early allograft dysfunction, hepatic artery thrombosis, and nonanastomotic biliary strictures) within the first year after the LT.
Among the cohort of 47 LTs with DCD-V grafts, 25 organ donors (53%) were women and the median (interquartile range [IQR]) age was 51 (44-59) years. Among the cohort of 542 LTs with DCD-III grafts, 335 organ donors (62%) were men and the median (IQR) age was 49 (37-57) years. Median (IQR) follow-up was 3.8 (2.1-6.3) years. In the DCD-V cohort, 30 recipients (64%) were men, and the median (IQR) age was 56 (48-64) years. Recipient survival in the DCD-V cohort was 87% at 1 year, 73% at 3 years, and 66% at 5 years after LT. Graft survival among recipients was 74% at 1 year, 61% at 3 years, and 57% at 5 years after LT. These survival rates did not differ statistically significantly from those in the DCD-III cohort. Incidence of postoperative complications did not differ between the groups. For example, the occurrence of early allograft dysfunction after the LT was found to be 13 (31%) in the DCD-V cohort and 219 (45%) in the DCD-III cohort. The occurrence of nonanastomotic biliary strictures after the LT was found to be 7 (15%) in the DCD-V cohort and 83 (15%) in the DCD-III cohort.
Conclusions and Relevance
The findings of this cohort study suggest that LTs with DCD-V grafts yield similar outcomes as LTs with DCD-III grafts; therefore, grafts donated after euthanasia may be a justifiable option for increasing the organ donor pool. However, grafts from these donations should be considered high-risk grafts that require an optimal donor selection process and logistics.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Accepted for Publication: April 16, 2020.
Corresponding Author: Wojciech G. Polak, MD, PhD, Division of Hepato-Pancreato-Biliary and Transplant Surgery, Department of Surgery, Erasmus MC University Medical Center, PO Box 2040, 3000 CA Rotterdam, the Netherlands (email@example.com).
Published Online: August 5, 2020. doi:10.1001/jamasurg.2020.2479
Author Contributions: Drs van Reeven and Polak had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: van Reeven, Ysebaert, Alwayn, IJzermans, Polak.
Acquisition, analysis, or interpretation of data: van Reeven, Gilbo, Monbaliu, van Leeuwen, Porte, van Hoek, Meurisse, Detry, Coubeau, Ciccarelli, Berrevoet, Vanlander, IJzermans, Polak.
Drafting of the manuscript: van Reeven, IJzermans, Polak.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: van Reeven, Gilbo, van Leeuwen.
Administrative, technical, or material support: van Reeven, Monbaliu, Porte, Ysebaert, van Hoek, Meurisse, Ciccarelli.
Supervision: van Leeuwen, Porte, Ysebaert, Alwayn, Detry, Berrevoet, Vanlander, IJzermans, Polak.
Other—coordinator of the study: van Reeven.
Conflict of Interest Disclosures: Dr van Hoek reported receiving grants from Zambon Pharma, Astellas Pharma, and Chiesi Pharma and personal fees from Norgine outside the submitted work. No other disclosures were reported.
Additional Contributions: Xavier Rogiers, MD, Ghent University Hospital, assisted in data collection and manuscript revision. Jacques Pirenne, PhD, University Hospitals Leuven, provided additional survival rate data on liver transplants with donation after brain death in Belgium. The Landelijk Overleg Levertransplantatie Dutch Liver Transplant Committee and the Belgian Liver and Intestinal Advisory Committee endorsed this project. Eurotransplant provided required data. None of the named individuals and groups received financial compensation for their contributions.
Additional Information: Xavier Rogiers, MD, died November 20, 2019.
You currently have no searches saved.